enGene (NASDAQ:ENGN) Posts Quarterly Earnings Results

enGene (NASDAQ:ENGN) issued its earnings results on Monday. The company reported ($0.44) EPS for the quarter, topping the consensus estimate of ($0.55) by $0.11, Zacks reports.

Here are the key takeaways from enGene’s conference call:

• Management attributes a combined effect of protocol amendments (T1 re‑resection, TA reinduction, routine biopsy) plus improved clinical execution for an estimated ≈21 percentage‑point improvement in the six‑month complete response rate.
• The program has received RMAT and CDRP designations and aligned the primary endpoint with the FDA to CR “at any time,” and management says ongoing SAP discussions increase confidence toward approval.
• Management states the safety database (the largest in the space at 125 patients) is sufficient and reports tolerability as near “best‑in‑class” with treatment discontinuations around 1–2%.
• They emphasize strong commercial fit in community urology: a non‑viral therapy with simple storage/handling, short clinic administration potentially by APP/staff, favorable buy‑and‑bill economics, and pricing flexibility to maximize market value.
• Company reports a cash runway into the second half of 2028, expects a potential approval in 2027, and plans interim 12‑month data updates (Q2 conference and H2), supporting a near‑term BLA path.

enGene Stock Performance

NASDAQ:ENGN opened at $6.94 on Wednesday. The company has a current ratio of 6.30, a quick ratio of 6.30 and a debt-to-equity ratio of 0.09. The firm has a 50-day moving average price of $9.50 and a two-hundred day moving average price of $8.11. enGene has a twelve month low of $2.65 and a twelve month high of $12.25. The company has a market capitalization of $464.91 million, a P/E ratio of -3.08 and a beta of -0.29.

Analysts Set New Price Targets

Several analysts recently commented on ENGN shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of enGene in a research note on Friday, January 9th. HC Wainwright reaffirmed a “buy” rating and issued a $25.00 target price on shares of enGene in a report on Monday. UBS Group lifted their price target on shares of enGene from $4.00 to $10.00 and gave the company a “neutral” rating in a research report on Wednesday, November 12th. Morgan Stanley boosted their price target on enGene from $18.00 to $19.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 12th. Finally, Raymond James Financial reaffirmed a “strong-buy” rating and issued a $27.00 price objective on shares of enGene in a research note on Monday. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $23.29.

Institutional Trading of enGene

Several large investors have recently modified their holdings of ENGN. Siren L.L.C. purchased a new position in shares of enGene during the 4th quarter worth approximately $30,126,000. Braidwell LP lifted its stake in enGene by 38.2% in the 4th quarter. Braidwell LP now owns 3,131,319 shares of the company’s stock valued at $28,276,000 after buying an additional 865,000 shares in the last quarter. Janus Henderson Group PLC acquired a new stake in enGene during the 4th quarter valued at $17,110,000. MPM Bioimpact LLC increased its position in enGene by 247.1% during the fourth quarter. MPM Bioimpact LLC now owns 1,840,898 shares of the company’s stock worth $16,623,000 after buying an additional 1,310,599 shares in the last quarter. Finally, Millennium Management LLC increased its position in enGene by 7,214.0% during the fourth quarter. Millennium Management LLC now owns 1,499,520 shares of the company’s stock worth $13,541,000 after buying an additional 1,479,018 shares in the last quarter. 64.16% of the stock is currently owned by institutional investors and hedge funds.

About enGene

enGene, Inc is a clinical‐stage biopharmaceutical company focused on the development of gene‐based therapeutics for oncology. The company’s core technology is the EnGene Delivery Vehicle (EDV) platform, which employs nonliving, bacterially derived minicells to transport therapeutic payloads directly to tumor cells. By combining targeted delivery with potent payloads, enGene aims to improve the precision and efficacy of cancer treatments while reducing off‐target toxicity.

Through its EDV platform, enGene has advanced multiple therapeutic candidates into preclinical and clinical stages.